Novel Interventions for the Diverse Population of Australians with Bronchiectasis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/633235

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Bronchiectasis is a chronic lung condition in which infection causes wheeze, breathlessness, fatigue and sputum production - markedly reducing quality of life and requiring repeated hospital admissions. Risk of hospitalisation due to the disease is up to 9-fold higher in Indigenous vs other Australians. This research will examine two new, low-cost therapies with excellent potential to treat bronchiectasis: a new antibiotic, Azithromycin, and a mucus-clearance agent, hypertonic saline.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $726,822.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Respiratory Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

acute and chronic lung infections | antibiotic therapy | antibiotics | bronchial disease | clinical trial | hypertonic saline | indigenous health | novel therapeutic | quality of life

Related Links